Home
Thursday, June 30, 2016
Session 1: Quantification of burden of disease
Chairs: Victor de Ledinghen (F) & Mary Rinella (US)
Modeling the epidemic of NAFLD and burden on healthcare system
Homi Razavi (US)
Variability of disease state transitions based on clinical phenotype and country of origin
Lawrence Serfaty (F)
The burden of NASH in pathology: how to recognize and how to score
Pierre Bedossa
Session 2: NAFLD and non-hepatic outcomes
Chairs: Saul Karpen (US) & Stanislas Pol (F)
NAFLD and cardiovascular disease: what is the connection?
Mary Rinella (US)
NAFLD and cancer prediction: mechanistic and clinical implications
Yujin Hoshida (US)
Reproductive health in NAFLD
Sophie Christin-Maitre (F)
Lifestyle and cancer
Jean-François Dufour (SWI)
Session 3: Best practices in managing NAFLD outside of hepatologists office
Chairs: Hélène Hanaire (F) & Arun Sanyal (US)
Diabetes and NAFLD- the hepatologists perspective
Vlad Ratziu (F)
Does diabetes control and the means for achieving control affect various phenotypes of NAFLD
Kenneth Cusi (US)
Session 4: Emerging toolkit for NAFLD
Chairs: Jérôme Boursier (F) & Jeffrey Schwimmer (US)
How MR technology may help the clinician
Claude Sirlin (US)
In vitro liver models and their applications for NASH
Ajit Dash (US)
Immune activators of disease progression-diagnostic and therapeutic implications
Gyongyi Szabo (US)
Friday, July 1, 2016
Session 5: Bile acids and NAFLD
Chairs: Phillip Hylemon (US) & Raoul Poupon (F)
Separating the metabolic benefits from lipoprotein abnormalities associated with FXR agonists-gut vs liver effect
Saul Karpen (US)
Non-FXR mediated benefits of bile acids on NAFLD
Huiping Zhou (US)
Session 6: The microbiome in metabolic syndrome of NAFLD
Chairs: Harry Sokol (F) & Gyongyi Szabo (US)
The microbiome in liver disease- moving from description to mechanisms
Patrick Gillevet (US)
The bile acid biome and its relevance for NAFLD and oncogenesis
Phillip Hylemon (US)
Session 7: Regulatory issues in NAFLD
Moderator: Patrick Marcellin (F)
Special Lecture: Update from the Liver Forum and the IOM initiative
Veronica Miller (US)